Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE versus GEMIFLOXACIN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE versus GEMIFLOXACIN MESYLATE.
CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE vs GEMIFLOXACIN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
Otic suspension: 3 drops (0.25 mL) into affected ear(s) twice daily for 7 days. Each drop contains ciprofloxacin HCl (equivalent to 0.2 mg ciprofloxacin base) and hydrocortisone 1 mg.
320 mg orally once daily for 7-14 days
None Documented
None Documented
Ciprofloxacin: ~4-5 hours (normal renal function); prolonged to 8-10 hours in severe renal impairment (CrCl <30 mL/min). Hydrocortisone: ~1.5-2 hours.
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Ciprofloxacin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; ~15-20% as metabolites; ~20-30% in feces via biliary excretion and transintestinal secretion. Hydrocortisone: metabolized in liver, metabolites excreted renally.
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic